iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

In This Article:

Last week, you might have seen that iTeos Therapeutics, Inc. (NASDAQ:ITOS) released its third-quarter result to the market. The early response was not positive, with shares down 7.8% to US$8.46 in the past week. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

View our latest analysis for iTeos Therapeutics

earnings-and-revenue-growth
NasdaqGM:ITOS Earnings and Revenue Growth November 15th 2024

Taking into account the latest results, the current consensus, from the five analysts covering iTeos Therapeutics, is for revenues of US$7.48m in 2025. This implies a disturbing 79% reduction in iTeos Therapeutics' revenue over the past 12 months. Per-share losses are expected to explode, reaching US$4.54 per share. Before this latest report, the consensus had been expecting revenues of US$7.40m and US$5.36 per share in losses. While the revenue estimates were largely unchanged, sentiment seems to have improved, with the analysts upgrading their numbers and making a notable improvement in losses per share in particular.

The average price target held steady at US$34.50, seeming to indicate that business is performing in line with expectations. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on iTeos Therapeutics, with the most bullish analyst valuing it at US$47.00 and the most bearish at US$22.00 per share. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

Of course, another way to look at these forecasts is to place them into context against the industry itself. We would highlight that revenue is expected to reverse, with a forecast 71% annualised decline to the end of 2025. That is a notable change from historical growth of 12% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 22% per year. It's pretty clear that iTeos Therapeutics' revenues are expected to perform substantially worse than the wider industry.

The Bottom Line

The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. The consensus price target held steady at US$34.50, with the latest estimates not enough to have an impact on their price targets.

Waiting for permission
Allow microphone access to enable voice search

Try again.